Clinical Trial Update: Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Ivosidenib monotherapy to Azacitidine monotherapy in IDH1-mutant, hypomethylating agent-naive myelodysplastic syndromes (MDS) that is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Tibsovo (ivosidenib)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS) | Phase 3 | Status: RECRUITING